Park Square has placed William Hodder as Chief Executive Officer at NFlection Therapeutics, Inc.
| less than a minute read
NFlection Therapeutics Appoints William Hodder as CEO and Expands Leadership Team to Accelerate Development of Targeted Treatments for Rare Diseases
Get in touch
Get in touch
NFlection Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for rare RASopathies, today announced that it has appointed William Hodder as CEO.
Get in touch
Get in touch
Latest Insights
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-01-21-26-53-841-6a97431d406533fea8d4615c.gif)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-01-15-07-30-357-6a96ea32ce35c90f7ee74028.jpg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-08-24-14-26-15-201-6a8c5487b4553f6e28c0bcb7.jpg)
/Passle/58a5cb8db00e8110e83aa395/SearchServiceImages/2026-08-19-20-29-57-758-6a8612450e2b381c3863fcf2.jpg)